Sean Dillon provides due diligence and advisory services to private equity firms investing in the healthcare sector.

His work focuses on illustrating the policy, regulatory, and reimbursement considerations for transactions across the physician services, pharma services, and post-acute care verticals.

Before joining Avalere, Sean served as vice president of the Legal, Economic and Regulatory Affairs team at Gerson Lehrman Group, supporting the research of public and private equity investors through conversations with senior professionals in the fields of law and public policy. In this capacity he hosted regular interviews with former officials from the Centers for Medicare & Medicaid Services, the US Department of Health and Human Services, former members of Congress, and Congressional staff members with respect to federal legislation and rulemaking impacting investible opportunities in the healthcare sector.

Sean has a BA in Spanish language and literature from Marist College and an MA in international affairs from the George Washington University.

Authored Content


In response to IRA provisions, life sciences companies should reevaluate their pipeline investment and development strategies.

Continued shifts in Medicare Advantage enrollment introduce new value-based care opportunities for patients with ESRD.

The IRA’s drug price negotiation policies, extended marketplace subsidies, and Part D redesign will impact investors’ current portfolios and investment strategy in the future.

A recent Avalere analysis of Medicare Fee-for-Service (FFS) data illustrates that treating major depressive disorder (MDD) in Medicare-eligible beneficiaries results in a 4% reduction in total cost compared to untreated patients, highlighting the importance of incentivizing adequate provider supply and payment in the geriatric psychiatry market.

A potential recession due to job losses and business closings as a result of COVID-19 will cause shifts in the payer mix and, ultimately, revenue dynamics for physician practices.